Metis Precision Medicine

About:

Metis Precision Medicine is a B-Corp founded with the vision of bringing powerful cancer therapies to patients in need.

Website: http://www.metisprecisionmedicine.org

Top Investors: Growth Engine, Club degli Investitori, 3LB Seed Capital Srl, Italian Angels for Biotech

Description:

Metis Precision Medicine is a B-Corp founded with the vision of bringing powerful cancer therapies to patients in need. Metis owns the intellectual property of a suite of anti-Met monoclonal antibodies (mAbs), with different and unique mechanisms of action, and is currently seeking investors, biotech or pharmaceutical companies interested in acquiring the relevant platform technology on a global basis.

Total Funding Amount:

1.25M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Turin, Piemonte, Italy

Founded Date:

2017-01-01

Founders:

Carla Boccaccio, Paolo Comoglio

Number of Employees:

1-10

Last Funding Date:

2022-03-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai